DPP4 inhibitors and cardiovascular outcomes: safety on heart failure
نویسندگان
چکیده
منابع مشابه
Cardiovascular safety of dipeptidyl peptidase-4 inhibitors: recent evidence on heart failure.
The cardiovascular safety of DPP4 inhibitors as a class, especially in regards to heart failure, has been questioned after the publication of first trials (SAVOR-TIMI 53 and EXAMINE) assessing the cardiovascular risks of DPP4 inhibitors alogliptin and sitagliptin in 2013. Although there were no increased risks in composite cardiovascular outcomes, the SAVOR-TIMI 53 trial reported a 27% increase...
متن کاملIs there any difference between Vitamin D deficiency among heart failure and Non-heart failure elderly with cardiovascular disease?
Vitamin D deficiency is common among the elderly with and without heart failure (HF). This study was designed to identify the degree of vitamin D deficiency among HF and Non- HF elderly with cardiovascular disease. In this study, fifty hospitalized elderly patients with HF (26 women and 24 men, age range 60-90 years) and fifty elderly without HF were randomly selected. The level of serum 25-hyd...
متن کاملTNF inhibitors and Heart Failure
John J. Cush, Kathryn H. Dao, Catalina Orozco Chronic systemic inflammation yields a notable and proportional risk for myocardial infarction, coronary artery disease, heart failure and cardiovascular (CV) death. The role of tumor necrosis factor (TNF) in the pathogenesis of cardiovascular events and congestive heart failure (CHF) in rheumatoid arthritis (RA) has been well documented (1-4). TNFα...
متن کاملDipeptidyl Peptidase 4 Inhibitors and the Risk of Cardiovascular Disease in Patients with Type 2 Diabetes: A Tale of Three Studies
Dipeptidyl peptidase 4 (DPP4) inhibitors have been touted as promising antihyperglycemic agents due to their beneficial effects on glycemia without inducing hypoglycemia or body weight gain and their good tolerability. Beyond their glucose-lowering effects, numerous clinical trials and experimental studies have suggested that DPP4 inhibitors may exert cardioprotective effects through their plei...
متن کاملTreatments for Type 2 Diabetes; a Focus on DPP4 Inhibitors
New treatments for diabetes are always exciting in the beginning but as experience grows their position in management becomes less certain. This review focuses on DPP4 inhibitors and their place in management of type 2 diabetes. Although hypoglycaemia is rarely an issue, the effectiveness in reduction in blood sugar is greatest at the higher blood sugar levels, hence much of the value of using ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Heart Failure Reviews
سال: 2017
ISSN: 1382-4147,1573-7322
DOI: 10.1007/s10741-017-9617-4